cassava7
Senior Member (Voting Rights)
GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
https://www.gsk.com/en-gb/media/pre...ratory-syncytial-virus-rsv-vaccine-candidate/
- Data to be presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favourable safety profile
- Consistent high vaccine efficacy observed against LRTD in severe disease (94.1%), adults aged 70-79 years (93.8%) and in adults with underlying comorbidities (94.6%)
- High vaccine efficacy is consistent across RSV A and B strains
https://www.gsk.com/en-gb/media/pre...ratory-syncytial-virus-rsv-vaccine-candidate/